24 completed, 17 recruiting, 9 not yet recruiting, 7 active not recruiting. 57 Phase 1, 21 Phase 2, 3 Not applicable, 1 Phase 4.
Follow Metastatic Solid Tumors: new trials by email Literature Review of Metastatic Solid Tumors trials Research Report on Metastatic Solid Tumors
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Multicenter Randomized Open-Label Trial Evaluating ctDNA-Guided Interruption Versus Standard of Care Immune-Checkpoint Inhibitor (ICI) Therapy In Patients With Advanced / Metastatic Solid Tumors. Signatera Genome ultra-sensitive ctDNA blood test - NSCLC (Advanced Non-small Cell Lung Cancer), NSCLC (Non-small Cell Lung Cancer) | Not applicable | Not yet recruiting | Natera, Inc. | 920 | 2027-01-01 | 2026-10-27 |
| A Study of IOV-5001 in Adults With Advanced Solid Tumors IOV-5001 - Advanced Solid Tumors, Non-Small Cell Lung Cancer | Phase 1 / Phase 2 | Not yet recruiting | Iovance Biotherapeutics, Inc. | 106 | 2026-09-01 | 2026-09-15 |
| SLR-108 PET Imaging in Subjects With Metastatic Solid Tumors SLR-108, SLX-1411 - Metastatic Solid Tumors | Phase 1 | Recruiting | Solve Therapeutics | 70 | 2026-08-04 | 2026-08-10 |
| Study of QLS5308 in Patients With Advanced Solid Tumors QLS5308 IV infusion - Metastatic Solid Tumors | Phase 1 | Not yet recruiting | Qilu Pharmaceutical Co., Ltd. | 192 | 2026-03-28 | 2026-03-10 |
| Phase 1/2 Study of EB-NK-301 (Allogeneic TROP2-CAR NK Cells) in Advanced TROP2-Expressing Solid Tumors EB-NK-301, Fludarabine - Advanced Solid Tumors, Metastatic Solid Tumors | Phase 1 / Phase 2 | Recruiting | Beijing Biotech | 60 | 2026-03-02 | 2026-05-15 |
| ADCX-020 for the Treatment of Patients With Locally Advanced or Metastatic Cancers ADCX-020 - Advanced Malignancy, Advanced Solid Cancers | Phase 1 | Recruiting | Adcytherix SAS | 290 | 2026-02-23 | 2026-06-08 |
| Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid Tumors Daraxonrasib, Elironrasib, Zoldonrasib - Advanced Solid Tumors, Metastatic Solid Tumors | Phase 1 / Phase 2 | Recruiting | Revolution Medicines, Inc. | 370 | 2026-01-30 | 2026-08-03 |
| Image-Guided 125I Seed Implantation Plus Standard Systemic Therapy for Patients With Multiple Metastatic Lesions Standard-of-Care Systemic Therapy, Iodine-125 (125I) Seed Implantation - Metastatic Solid Tumors | Phase 2 | Not yet recruiting | Li Min | 120 | 2026-01-01 | 2026-01-12 |
| Rare Tumor Focused Platform Study of Innovative Therapies and Technologies (PLATFORM2) BL-B01D1, VSV injection, CVL006 - Rare Malignant Neoplasm, Advanced Solid Tumors | Phase 1 / Phase 2 | Not yet recruiting | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 600 | 2026-01-01 | 2025-12-29 |
| Study of QLC5513 in Combination With Epalolimab Tovolimab (QL1706) ± Platinum in Patients With Advanced or Metastatic Malignant Solid Tumors QLC5513 IV infusion, QL1706, IV infusion, platinum, IV infusion - Metastatic Solid Tumors | Phase 1 / Phase 2 | Not yet recruiting | Qilu Pharmaceutical Co., Ltd. | 290 | 2025-12-30 | 2025-12-09 |
| The Sarah Nanotechnology System for Treatment of Advanced Metastatic Solid Tumors Using Hyperthermia. The Sarah Nanotechnology System - intended to deliver thermal energy to malignant cells for the purpose of thermal destruction of these cells in patients with advanced metastatic solid tumors. - Metastatic Solid Tumors, Stage 4 Cancer | Not applicable | Recruiting | New Phase Ltd. | 12 | 2025-12-16 | 2026-05-15 |
| A Study of BPR-6023021 in Advanced Solid Tumors With Bone Metastases BPR-6023021 for injection - Metastatic Solid Tumors | Phase 1 / Phase 2 | Not yet recruiting | Chengdu Syncor Pharmaceutical Co., Ltd. | 195 | 2025-11-19 | 2025-11-25 |
| Phase Ia/Ib Study of CKD-512 Alone and in Combination With Pembrolizumab in Subjects With Advanced or Metastatic Solid Tumors CKD-512, Pembrolizumab - Advanced Solid Tumors, Metastatic Solid Tumors | Phase 1 | Recruiting | Chong Kun Dang Pharmaceutical | 60 | 2025-10-16 | 2026-02-02 |
| A Study of DS3610a in Participants With Advanced Solid Tumor DS3610a - Solid Tumors, Metastatic Solid Tumors | Phase 1 | Recruiting | Daiichi Sankyo | 70 | 2025-10-09 | 2026-09-18 |
| BEACON-1: Study of AVZO-103 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Urothelial Cancer or Other Solid Tumors (AVZO-103-1001) AVZO-103, Combination Agent - Solid Tumor Cancer, Locally Advanced | Phase 1 / Phase 2 | Recruiting | Avenzo Therapeutics, Inc. | 355 | 2025-10-02 | 2026-10-05 |
| SLV-324 Treatment of Metastatic Solid Tumors SLV-324 intravenous (IV infusion) - Metastatic Solid Tumors | Phase 1 | Recruiting | Solve Therapeutics | 70 | 2025-08-25 | 2026-02-23 |
| A Study of SKB107 in Advanced Solid Tumors With Bone Metastases SKB107 for injection - Metastatic Solid Tumors | Phase 1 | Recruiting | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | 90 | 2025-08-15 | 2026-05-08 |
| A Study of ERAS-4001 in Patients With Advanced or Metastatic Solid Tumors. ERAS-4001, ERAS-4001 in combination - Metastatic Solid Tumors | Phase 1 | Recruiting | Erasca, Inc. | 200 | 2025-08-06 | 2025-12-03 |
| A Multicenter, Prospective, Non-Interventional Real-World Study of Iparomlimab and Tuvonralimab Injection (QL1706) in the Treatment of Locally Advanced or Metastatic Solid Tumors Observation arm - Solid Tumor Cancer, Metastatic Solid Tumors | Not yet recruiting | PENG YUAN | 90 | 2025-07-30 | 2025-07-02 | |
| A Study to Evaluate INCB177054 in Participants With Select Advanced or Metastatic Solid Tumors INCB177054, Retifanlimab - Solid Tumors, Advanced Solid Tumors | Phase 1 / Phase 2 | Terminated | Incyte Corporation | 9 | 2025-06-30 | 2026-09-02 |
Showing 20 of 70. Sign in to see all of them.
Neoplasm Metastasis (15) · Neoplasms (14) · Carcinoma, Non-Small-Cell Lung (9) · Colorectal Neoplasms (5) · Lung Neoplasms (5) · Breast Neoplasms (3) · Sarcoma (3) · Stomach Neoplasms (3) · Carcinoma (2) · Carcinoma, Renal Cell (2) · Colonic Neoplasms (2) · Head and Neck Neoplasms (2) · Liver Neoplasms (2) · Melanoma (2) · Pancreatic Neoplasms (2)
Neoplasms (17) · Pathological Conditions, Signs and Symptoms (17) · Pathologic Processes (16) · Neoplastic Processes (15) · Neoplasms by Site (13) · Digestive System Diseases (12) · Digestive System Neoplasms (11) · Lung Diseases (10) · Respiratory Tract Diseases (10) · Respiratory Tract Neoplasms (10) · Thoracic Neoplasms (10) · Bronchial Neoplasms (9) · Carcinoma, Bronchogenic (9) · Gastrointestinal Diseases (9) · Gastrointestinal Neoplasms (9)
pembrolizumab (5) · Carboplatin (3) · Cetuximab (3) · Gemcitabine (3) · 130-nm albumin-bound paclitaxel (2) · Albumin-Bound Paclitaxel (2) · Infusions, Intravenous (2) · Injections (2) · Panitumumab (2) · atezolizumab (2) · repotrectinib (2) · (2,4-dihydroxy-5-isopropylphenyl)-(5-(4-methylpiperazin-1-ylmethyl)-1,3-dihydroisoindol-2-yl)methanone (1) · Alpelisib (1) · Antibodies, Bispecific (1) · BMS 181339 (1)
Incyte Corporation (3) · Turning Point Therapeutics, Inc. (3) · Avenzo Therapeutics, Inc. (2) · Daiichi Sankyo (2) · EMD Serono Research & Development Institute, Inc. (2) · Erasca, Inc. (2) · Genentech, Inc. (2) · Hadassah Medical Organization (2) · Merck Sharp & Dohme LLC (2) · Qilu Pharmaceutical Co., Ltd. (2) · Solve Therapeutics (2) · AbbVie (1) · Adcytherix SAS (1) · Alphamab (Australia) Co Pty Ltd. (1) · Ankara Etlik City Hospital (1)
United States (42) · China (14) · Spain (13) · France (12) · Australia (11) · Canada (11) · South Korea (11) · United Kingdom (8) · Italy (7) · Belgium (6) · Japan (5) · Denmark (4) · Israel (4) · Singapore (4) · Taiwan (4)
Gerri Lee (2) · Alexander JB McEwan, MB,FRCPC (1) · Apostolia Tsimberidou, MD, PHD (1) · Arlene Chan (1) · Dan Levitt, M.D. (1) · Eiji Ueda, MD, PhD, MBA (1)
PMID 22025163, PMID 25043054, PMID 25239610, PMID 26565381, PMID 26884591, PMID 27251275, PMID 27372738, PMID 30093503, PMID 31838007, PMID 31838015, PMID 32269053, PMID 32508818, PMID 33646820, PMID 34427452, PMID 34814185, PMID 35338084, PMID 35354274, PMID 35728046, PMID 35939768, PMID 36394153, PMID 38197815, PMID 38917788, PMID 39509670, PMID 39549678, PMID 39929671, PMID 40341199, PMID 41639379, PMID 41724817
2023 (3), 2025 (2), 2017 (1), 2018 (1), 2019 (1)